logo
SpaceX Starship Destroyed in Third Straight Fiery Test Setback

SpaceX Starship Destroyed in Third Straight Fiery Test Setback

Mint5 days ago

(Bloomberg) -- SpaceX's colossal Starship rocket suffered a leak, tumbled out of control in space and disintegrated as it hurtled back to Earth during a test flight on Tuesday, in a third setback in a row for the Elon Musk-led company.
The launch system, comprised of the Starship upper portion and its Super Heavy booster, thundered off the company's launchpad in South Texas at around 6:36 p.m. local time. As the rocket lifted off, around 1.1 million people tuned in on X.
A few minutes into the flight, the recycled Super Heavy booster separated from the Starship upper portion and fired its engines. But as it maneuvered itself into position and plunged back to Earth, it suffered an apparent problem and exploded, SpaceX commentators said, adding that it was expected to make a hard splashdown in the Gulf of Mexico regardless.
SpaceX then appeared to fall short of another key milestone planned for the mission: using Starship to deploy a slate of dummy satellites. Starship made it to space but launch commentators said the vehicle's bay door didn't open as expected, cutting that test short. The satellite simulators are designed to mimic upgraded Starlink internet satellites the rocket is meant to carry when it's operational.
Then around 35 minutes into the mission, as Starship hurtled toward Earth's atmosphere on its journey home, the livestream started to cut in and out. At one point, SpaceX commentator Dan Huot told viewers the vehicle had lost control and that the rocket was spinning, unable to set itself up for a controlled reentry and to withstand the intense heat and pressure of the atmosphere during descent. The vehicle 'met its demise,' said another SpaceX commentator, Jessie Anderson.
'We have been dealing with some leaks on the ship,' Huot said, referring to its fuel tank systems. 'This is also what led to that loss of attitude control.'
SpaceX stressed that the company learns from every test flight. 'We're going to learn, iterate and iterate over and over again,' Anderson said.
After the launch, Musk had planned an all-hands-style talk with employees at 8 p.m. local time out of the company's newly incorporated city, Starbase, in South Texas. As of 9 p.m., it hadn't started and there was no word on why. The mission came as Musk, the world's richest person, says he is stepping back from his political work in Washington and focusing on his business empire.
The Federal Aviation Administration, which licenses Starship flights, said it was aware 'an anomaly occurred' and is actively working with SpaceX on the event. There are no reports of public injury or damage to public property, it added.
The stakes for Tuesday's flight were particularly high after flights in January and March were cut short just minutes after takeoff when the spacecraft exploded over the Gulf of Mexico, sending streams of debris raining down from the sky and disrupting air travel.
The results failed to live up to earlier flights when the vehicle made it to space, partially circled the globe, survived the plunge through the atmosphere and splashed into the ocean roughly as planned.
Starship is critical to Musk's and SpaceX's Mars vision. As the world's largest and most powerful launch system, Starship is meant to serve as the primary spacecraft for transporting people to the Red Planet and then bringing them back to Earth. Musk has recently declared that SpaceX will send a Starship rocket to Mars carrying robots built by his electric car company, Tesla Inc., as early as 2026 — an incredibly ambitious timeline.
SpaceX also holds contracts with NASA worth roughly $4 billion to land the agency's astronauts on the moon with Starship — making it a key part of America's space ambitions.
SpaceX blamed the botched January test on unexpectedly intense vibrations that worsened a propellant leak, leading to fires throughout the vehicle. As for the March failure, the company said that one of Starship's Raptor engines likely had a hardware issue, causing propellants to mix together at the wrong time and ultimately leading to the explosion.
The company said it led investigations into each of the incidents and made fixes to prevent the problems from happening again. The company also said that the two failures were 'distinctly different' from one another, despite the explosions occurring around the same time in each flight. Additionally, future Starship vehicles will be equipped with new 'Raptor 3' engines that are supposed to be more reliable.
Subscribe Now: Business of Space newsletter, a weekly look at the inside stories of investments beyond Earth.
Despite the repeated flight failures, SpaceX was still able to 'catch' Starship's massive Super Heavy booster back at the rocket's launch tower following each flight — an impressive feat the company managed to do for the first time last year.
For this ninth launch, the company didn't attempt a midair capture of the vehicle. Instead, SpaceX chose to re-fly one of the Super Heavy boosters it caught previously — a first for the company.
Designed to be fully reusable, Starship will be much cheaper to fly than any other rocket, according to SpaceX, and will eventually replace the company's industry-leading Falcon 9 and Falcon Heavy rockets.
But to meet that promise of delivering a fully reusable rocket, SpaceX must refine its technique for recovering all of the pieces of Starship after launch.
(Updates with details on Musk's talk in eighth paragraph.)
More stories like this are available on bloomberg.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump-Musk ties strain as Isaacman ousted, Musk exits DOGE; NYT alleges drug use
Trump-Musk ties strain as Isaacman ousted, Musk exits DOGE; NYT alleges drug use

Economic Times

time13 hours ago

  • Economic Times

Trump-Musk ties strain as Isaacman ousted, Musk exits DOGE; NYT alleges drug use

AP (AP Photo/Matt Rourke, File) US president Donald Trump and tech billionaire Elon Musk appear to be drifting apart after a series of high-profile moves involving their close associates, political roles, and a damaging media report. Trump withdrew his pick of Jared Isaacman to lead NASA, while Musk exited his advisory role in the Department of Government Efficiency (DOGE). Trump pulls Isaacman's NASA nomination Trump on Saturday said he was rescinding the nomination of Isaacman, a private astronaut and payments entrepreneur, to head the US space agency. 'After a thorough review of prior associations, I am hereby withdrawing the nomination of Jared Isaacman to head NASA,' Trump wrote on his Truth Social platform. 'I will soon announce a new Nominee who will be Mission aligned, and put America First in Space.' Isaacman, founder of Shift4 Payments, has worked closely with Musk's SpaceX and is known for leading the first all-civilian space mission. His ties to Musk reportedly played a key role in his nomination. The New York Times reported that Trump decided to pull back after learning that Isaacman had previously donated to well-known Democratic candidates. Responding to that report, the White House told AFP in an email, 'It is essential that the next leader of NASA is in complete alignment with president Trump's America First agenda. The Administrator of NASA will help lead humanity into space and execute president Trump's bold mission of planting the American flag on the planet Mars.' Musk leaves DOGE amid growing scrutiny Appointed by the president himself, Musk became in-charge of DOGE, a key project aimed at cutting government spending. His appointment made headlines and sparked strong reactions from both supporters and many expected Musk to step down, his exit came shortly after he publicly disagreed with parts of Trump's policy plans. That added to growing concerns about his role in his time at DOGE, Musk pushed for major spending cuts. Several government agencies were shut down and thousands of jobs were cut. These changes led to public protests and raised questions about whether it was appropriate for someone running large private companies to be involved in such Musk led DOGE, his companies, including Tesla, SpaceX and Neuralink, continued to operate, Tesla shares fell sharply, and protests erupted following DOGE's sweeping budget cuts and the closure of several federal agencies. Musk denies drug use claims by NYT Meanwhile, Musk hit back at a New York Times report that accused him of regular drug use during the 2024 campaign newspaper reported that Musk had used ketamine, ecstasy, and mushrooms and even developed bladder issues from frequent ketamine use. It said he carried a pill box and it was unclear whether he continued using drugs after joining the Trump administration in rejected the claims on Saturday. 'To be clear, I am NOT taking drugs. The New York Times was lying their ass off,' he wrote on added, 'I tried 'prescription' ketamine a few years ago and said so on X, so this is not even news. It helps for getting out of dark mental holes, but haven't taken it since then.'When asked by a reporter if he knew about Musk's alleged drug use, Trump replied, 'I wasn't. I think Elon is a fantastic guy.'

Trump-Musk ties strain as Isaacman ousted, Musk exits DOGE; NYT alleges drug use
Trump-Musk ties strain as Isaacman ousted, Musk exits DOGE; NYT alleges drug use

Time of India

time14 hours ago

  • Time of India

Trump-Musk ties strain as Isaacman ousted, Musk exits DOGE; NYT alleges drug use

Live Events US president Donald Trump and tech billionaire Elon Musk appear to be drifting apart after a series of high-profile moves involving their close associates, political roles, and a damaging media report. Trump withdrew his pick of Jared Isaacman to lead NASA, while Musk exited his advisory role in the Department of Government Efficiency (DOGE).Trump on Saturday said he was rescinding the nomination of Isaacman, a private astronaut and payments entrepreneur, to head the US space agency.'After a thorough review of prior associations, I am hereby withdrawing the nomination of Jared Isaacman to head NASA,' Trump wrote on his Truth Social platform. 'I will soon announce a new Nominee who will be Mission aligned, and put America First in Space .'Isaacman, founder of Shift4 Payments, has worked closely with Musk's SpaceX and is known for leading the first all-civilian space mission. His ties to Musk reportedly played a key role in his New York Times reported that Trump decided to pull back after learning that Isaacman had previously donated to well-known Democratic to that report, the White House told AFP in an email, 'It is essential that the next leader of NASA is in complete alignment with president Trump's America First agenda. The Administrator of NASA will help lead humanity into space and execute president Trump's bold mission of planting the American flag on the planet Mars.'Appointed by the president himself, Musk became in-charge of DOGE, a key project aimed at cutting government spending. His appointment made headlines and sparked strong reactions from both supporters and many expected Musk to step down, his exit came shortly after he publicly disagreed with parts of Trump's policy plans. That added to growing concerns about his role in his time at DOGE, Musk pushed for major spending cuts. Several government agencies were shut down and thousands of jobs were cut. These changes led to public protests and raised questions about whether it was appropriate for someone running large private companies to be involved in such Musk led DOGE, his companies, including Tesla, SpaceX and Neuralink, continued to operate, Tesla shares fell sharply, and protests erupted following DOGE's sweeping budget cuts and the closure of several federal Musk hit back at a New York Times report that accused him of regular drug use during the 2024 campaign newspaper reported that Musk had used ketamine, ecstasy, and mushrooms and even developed bladder issues from frequent ketamine use. It said he carried a pill box and it was unclear whether he continued using drugs after joining the Trump administration in rejected the claims on Saturday. 'To be clear, I am NOT taking drugs. The New York Times was lying their ass off,' he wrote on added, 'I tried 'prescription' ketamine a few years ago and said so on X, so this is not even news. It helps for getting out of dark mental holes, but haven't taken it since then.'When asked by a reporter if he knew about Musk's alleged drug use, Trump replied, 'I wasn't. I think Elon is a fantastic guy.'

Immunotherapy Drugs Show Major Progress in Early-Stage Cancer
Immunotherapy Drugs Show Major Progress in Early-Stage Cancer

Mint

time18 hours ago

  • Mint

Immunotherapy Drugs Show Major Progress in Early-Stage Cancer

(Bloomberg) -- Drugs that boost the body's immune system to fight disease are showing promise in treating a variety of cancers in earlier stages, a development primed to expand their use and transform care for stubborn diseases like gastric and colon cancer. Immunotherapy treatments such as Opdivo from Bristol Myers Squibb Co., Imfinzi from AstraZeneca PLC, and Roche Holding AG's Tecentriq have become bestsellers by increasing survival times in a number of advanced cancers. Now the treatments are showing success against early and mid-stage cancers, according to results of large trials being presented at the American Society of Clinical Oncology meeting in Chicago this weekend. One highlight is that the drugs are preventing recurrences in operable tumors that are at high risk of relapsing. 'We're learning that immunotherapy may, in fact, be more effective when you have less of a tumor burden,' said Jean Bourhis, an oncologist at Lausanne University Hospital in Switzerland, who led a study on patients with squamous cell carcinoma of the head and neck. 'The key is using it earlier.' Treatment for that kind of head and neck cancer hasn't fundamentally changed in two decades. Use of Bristol's Opdivo in the study slashed the recurrence rate by nearly a quarter after three years when used after surgery to help prevent a relapse. This development could impact about 40% of people diagnosed with the disease, Bourhis said. In a study sponsored by AstraZeneca, researchers found that using the firm's Imfinzi drug before and after surgery reduced the odds by 29% over a two-year period that a nasty type of operable gastric or gastroesophageal junction cancer would relapse or progress. The development sets the stage for a new global standard of care for such cancers, which are particularly common in Asia, doctors said. In a study on colon cancer, sponsored by the National Cancer Institute, oncologists found that adding Roche's Tecentriq to standard chemotherapy used after surgery significantly bolstered the number of patients who were alive and disease free after three years. The finding represents a major advance in the field, the study's lead investigator said, and could help roughly 15% of patients with operable colon cancer that has spread to the lymph nodes. 'We have a real potential to cure many of these patients,' the investigator, Mayo Clinic oncologist Frank Sinicrope, said in an interview. For the companies, expanding the use of immune drugs to earlier stage cancers may provide a new source of revenue to an aging group of blockbusters. 'This brings a commercial opportunity,' said Susan Galbraith, AstraZeneca's executive vice president for oncology research. The company has discussed with regulators the potential for the drug to get approved for the new use case, she said, declining to go into detail of where those talks stood. Merck & Co.'s immunotherapy Keytruda, which is featured in multiple studies at ASCO, shows how lucrative treating disease early can be. It has become the world's best-selling medicine thanks in part to its use in early cancer. Of the drug's 41 approved uses, nine are now for early-stage disease. Treating cancer early is 'where our growth is,' Dean Li, head of research at Merck, said Thursday at an investor conference. 'But it's not just economic growth. This is where you can cure patients.' New immunotherapy results in head and neck cancer are poised to upend decades of medical practice. For patients with an aggressive form of head and neck cancer, the longstanding first-line treatment was to surgically remove the tumor and use chemotherapy and radiation to keep the disease at bay. The Opdivo study showed that adding the drug to the standard of care cut the risk of cancer recurrence three years after treatment by 24%. That finding comes on the heels of a successful head and neck study from Merck's rival Keytruda drug. In a big study presented in April, Keytruda reduced the risk of relapse when it was used both before and after surgery in head and neck patients. That potential new use is now under review by US regulators. In AstraZeneca's study being presented at ASCO, using Imfinzi before and after surgery was able to increase the number of people alive without a recurrence or disease progression after two years to 67.4% from 58.5%. 'For patients facing a high risk of relapse, this brings new hope for long-term survival,' said Yelena Y. Janjigian, an oncologist at New York's Memorial Sloan Kettering Cancer Center, who was lead investigator on the study. 'It is a pretty big deal.' Will Murray, a 52-year-old retired New York police detective, discovered he had a tumor at the junction of his esophagus and stomach in April 2022. It was operable, but he was at high risk of relapse. In an interview, he said the high death rate from this type of cancer terrified him. But Murray received one of the last spots in the AstraZeneca study and got into the immunotherapy arm. His tumor started shrinking even before the surgery. And since the operation, it hasn't come back, although he did suffer thyroid deficiency, a side effect of immune therapy drugs. Murray now has to eat carefully and can't sleep flat due to the stomach operation, but he can mostly live a normal life, including taking long walks and going on trips with his girlfriend. He credits the immunotherapy treatment trial for helping keep his tumors at bay. 'It saved my life,' Murray said. --With assistance from Danielle Chaves. More stories like this are available on

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store